Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 3/20 | 0.51 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8620522 | 1.00 | CCNE1 (0.51) | CCNE1CDK2CDK1CCNB1HPRT1 | |
| SCHEMBL465830 | 0.88 | CCNE1 (0.51) | CCNE1CDK2CDK1CCNB1HPRT1 | |
| SCHEMBL384146 | 0.84 | ADORA2A (0.54) | ADORA2AADORA1AHCY | |
| SCHEMBL6366274 | 0.84 | ADORA2A (0.54) | ADORA2AADORA1AHCY | |
| SCHEMBL29624179 | 0.82 | HPRT1 (0.56) | CCNE1CDK2CDK1CCNB1HPRT1 | |
| SCHEMBL9189595 | 0.82 | CCNE1 (0.49) | CCNE1CDK2CDK1CCNB1HPRT1 | |
| SCHEMBL3860363 | 0.82 | HPRT1 (0.56) | CCNE1CDK2CDK1CCNB1HPRT1 | |
| SCHEMBL9193126 | 0.82 | HPRT1 (0.56) | CCNE1CDK2CDK1CCNB1HPRT1 | |
| SCHEMBL3857976 | 0.82 | CCNE1 (0.57) | CCNE1CDK2CDK1CCNB1HSP90AA1 | |
| SCHEMBL3856997 | 0.79 | HPRT1 (0.71) | HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753762-B1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-7582758-B2 | producing cyclic phosphonic acid diesters prodrugs, used to improve the oral bioavailability; by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid; Adefovir drug target delivery to liver | METABASIS THERAPEUTICS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1753762-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | Metabasis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123729-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | PHOSPHO1, LPAR1, LPAR2 | CCNE1 988/4885CDK2 467/4885CDK1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.